Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Borr Drilling rugi bersih Q2 FY26 melebar ke USD 241,4 juta; revenue turun 6% menjadi USD 232,3 juta QoQ

Borr Drilling rugi bersih Q2 FY26 melebar ke USD 241,4 juta; revenue turun 6% menjadi USD 232,3 juta QoQ

ReutersReuters2026/08/11 21:50
  • Borr Drilling membukukan revenue kuartal II 2026 sebesar USD 232,3 juta, turun 6% dari kuartal I.
  • Rugi bersih melebar menjadi USD 241,4 juta dari USD 29 juta, dipicu beban pelunasan utang USD 176,3 juta.
  • Adjusted EBITDA kuartal II turun 51% menjadi USD 43,8 juta, di tengah penurunan rata-rata rig beroperasi menjadi 21,2.
  • Utilisasi teknis 98,4% dan utilisasi ekonomis 96,4%; sepanjang 2026 meraih 21 komitmen kontrak senilai USD 541 juta.
  • Perusahaan merampungkan refinancing utang, memperbesar fasilitas RCF menjadi USD 250 juta; usai kuartal membeli lima rig melalui JV 50/50.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Borr Drilling Ltd. published the original content used to generate this news brief via Cision (Ref. ID: 20260811:BIT:6581:0) on August 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.